[{"id":"b00fc8ee-1191-428e-8093-c4351326248c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00898456","created_at":"2021-01-18T03:27:05.038Z","updated_at":"2024-07-02T16:35:39.792Z","phase":"","brief_title":"Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT00898456","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABCB1 • ABCG2 • ABCC1","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2 • ABCC1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 01/01/2100","primary_completion_date":" 01/01/2100","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-17"},{"id":"c82e952a-157c-48ba-a630-e6d18c77d6e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00104923","created_at":"2021-02-08T07:52:09.320Z","updated_at":"2024-07-02T16:37:19.749Z","phase":"Phase 1","brief_title":"Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer","source_id_and_acronym":"NCT00104923","lead_sponsor":"California Cancer Consortium","biomarkers":" ABCC1","pipe":"","alterations":" ","tags":["ABCC1"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2005","start_date":" 02/01/2005","primary_txt":" Primary completion: 04/01/2017","primary_completion_date":" 04/01/2017","study_txt":" Completion: 04/01/2017","study_completion_date":" 04/01/2017","last_update_posted":"2017-07-19"}]